Blood Targets of Adjuvant Drugs Against COVID19

Overview

Journal J Blood Med

Publisher Dove Medical Press

Specialty Hematology

Date 2020 Jul 23

PMID 32694923

Citations 4

Authors

Pierpaolo Di Micco

Gianluca Di Micco

Vincenzo Russo

Maria Rita Poggiano

Ciro Salzano

Marijan Bosevski

Michele Imparato

Luca Fontanella

Andrea Fontanella

Affiliations

Soon will be listed here.

Abstract

While waiting for the vaccine and/or the best treatment for COVID19, several drugs have been identified as potential adjuvant drugs to counteract the viral action. Several drugs, in fact, have been suggested for their ancillary antiviral role. Viral proteases and peptidases, may interact with well-known drugs such as anticoagulants, antihypertensives, antiserotoninergics and immunomodulants. We here report a basic list of these drugs that include bioflavonoids, heparinoids, ACE inhibitors, angiotensin receptor blockers, antiserotoninergics, and monoclonal antibodies against cytokines that may interact with the viral cycle.

Citing Articles

Heparin and SARS-CoV-2: Multiple Pathophysiological Links.

Di Micco P, Imbalzano E, Russo V, Attena E, Mandaliti V, Orlando L Viruses. 2021; 13(12).

PMID: 34960754 PMC: 8705068. DOI: 10.3390/v13122486.

Natural Products for the Prevention and Control of the COVID-19 Pandemic: Sustainable Bioresources.

Singla R, He X, Chopra H, Tsagkaris C, Shen L, Kamal M Front Pharmacol. 2021; 12:758159.

PMID: 34925017 PMC: 8671886. DOI: 10.3389/fphar.2021.758159.

Antithrombotic and Anti-Inflammatory Effects of Fondaparinux and Enoxaparin in Hospitalized COVID-19 Patients: The FONDENOXAVID Study.

Cardillo G, Viggiano G, Russo V, Mangiacapra S, Cavalli A, Castaldo G J Blood Med. 2021; 12:69-75.

PMID: 33603528 PMC: 7886238. DOI: 10.2147/JBM.S285214.

Potential role of interferons in treating COVID-19 patients.

Haji Abdolvahab M, Moradi-Kalbolandi S, Zarei M, Bose D, Majidzadeh-A K, Farahmand L Int Immunopharmacol. 2020; 90:107171.

PMID: 33221168 PMC: 7608019. DOI: 10.1016/j.intimp.2020.107171.

References

Guo T, Fan Y, Chen M, Wu X, Zhang L, He T . Cardiovascular Implications of Fatal Outcomes of Patients With Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020; 5(7):811-818. PMC: 7101506. DOI: 10.1001/jamacardio.2020.1017. View

Li X, Zhang C, Liu L, Gu M . Existing bitter medicines for fighting 2019-nCoV-associated infectious diseases. FASEB J. 2020; 34(5):6008-6016. PMC: 7262065. DOI: 10.1096/fj.202000502. View

Ghiselli G . Heparin Binding Proteins as Therapeutic Target: An Historical Account and Current Trends. Medicines (Basel). 2019; 6(3). PMC: 6789896. DOI: 10.3390/medicines6030080. View

Pant S, Singh M, Ravichandiran V, Murty U, Srivastava H . Peptide-like and small-molecule inhibitors against Covid-19. J Biomol Struct Dyn. 2020; 39(8):2904-2913. PMC: 7212534. DOI: 10.1080/07391102.2020.1757510. View

Danser A, Epstein M, Batlle D . Renin-Angiotensin System Blockers and the COVID-19 Pandemic: At Present There Is No Evidence to Abandon Renin-Angiotensin System Blockers. Hypertension. 2020; 75(6):1382-1385. PMC: 7225046. DOI: 10.1161/HYPERTENSIONAHA.120.15082. View

Mahase E . Coronavirus covid-19 has killed more people than SARS and MERS combined, despite lower case fatality rate. BMJ. 2020; 368:m641. DOI: 10.1136/bmj.m641. View

Pedersen S, Ho Y . SARS-CoV-2: a storm is raging. J Clin Invest. 2020; 130(5):2202-2205. PMC: 7190904. DOI: 10.1172/JCI137647. View

Rice G, Thomas D, Grant P, Turner A, Hooper N . Evaluation of angiotensin-converting enzyme (ACE), its homologue ACE2 and neprilysin in angiotensin peptide metabolism. Biochem J. 2004; 383(Pt 1):45-51. PMC: 1134042. DOI: 10.1042/BJ20040634. View

Bersanelli M . Controversies about COVID-19 and anticancer treatment with immune checkpoint inhibitors. Immunotherapy. 2020; 12(5):269-273. PMC: 7117596. DOI: 10.2217/imt-2020-0067. View

10.

Jo S, Kim H, Kim S, Shin D, Kim M . Characteristics of flavonoids as potent MERS-CoV 3C-like protease inhibitors. Chem Biol Drug Des. 2019; 94(6):2023-2030. PMC: 7162010. DOI: 10.1111/cbdd.13604. View

11.

Chen G, Wu D, Guo W, Cao Y, Huang D, Wang H . Clinical and immunological features of severe and moderate coronavirus disease 2019. J Clin Invest. 2020; 130(5):2620-2629. PMC: 7190990. DOI: 10.1172/JCI137244. View

12.

Henry C, Zaizafoun M, Stock E, Ghamande S, Arroliga A, White H . Impact of angiotensin-converting enzyme inhibitors and statins on viral pneumonia. Proc (Bayl Univ Med Cent). 2019; 31(4):419-423. PMC: 6414001. DOI: 10.1080/08998280.2018.1499293. View

13.

Wan J, Sun W, Li X, Ying W, Dai J, Kuai X . Inflammation inhibitors were remarkably up-regulated in plasma of severe acute respiratory syndrome patients at progressive phase. Proteomics. 2006; 6(9):2886-94. PMC: 7168070. DOI: 10.1002/pmic.200500638. View

14.

Buczek-Thomas J, Rich C, Nugent M . Hypoxia Induced Heparan Sulfate Primes the Extracellular Matrix for Endothelial Cell Recruitment by Facilitating VEGF-Fibronectin Interactions. Int J Mol Sci. 2019; 20(20). PMC: 6829205. DOI: 10.3390/ijms20205065. View

15.

Lai M, Cavanagh D . The molecular biology of coronaviruses. Adv Virus Res. 1997; 48:1-100. PMC: 7130985. View

16.

. Some drugs for COVID-19. Med Lett Drugs Ther. 2020; 62(1595):49-50. View

17.

Zhou F, Yu T, Du R, Fan G, Liu Y, Liu Z . Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet. 2020; 395(10229):1054-1062. PMC: 7270627. DOI: 10.1016/S0140-6736(20)30566-3. View

18.

Guo H, de Vries E, McBride R, Dekkers J, Peng W, Bouwman K . Highly Pathogenic Influenza A(H5Nx) Viruses with Altered H5 Receptor-Binding Specificity. Emerg Infect Dis. 2016; 23(2):220-231. PMC: 5324792. DOI: 10.3201/eid2302.161072. View

19.

Milewska A, Nowak P, Owczarek K, Szczepanski A, Zarebski M, Hoang A . Entry of Human Coronavirus NL63 into the Cell. J Virol. 2017; 92(3). PMC: 5774871. DOI: 10.1128/JVI.01933-17. View

20.

Lang J, Yang N, Deng J, Liu K, Yang P, Zhang G . Inhibition of SARS pseudovirus cell entry by lactoferrin binding to heparan sulfate proteoglycans. PLoS One. 2011; 6(8):e23710. PMC: 3161750. DOI: 10.1371/journal.pone.0023710. View